Former ImClone CEO Makes $100 Million Acquisition

October 26, 2010 | Sam Waksal, former ImClone CEO, has announced that his drug company Kadmon Pharmaceuticals has bought Three Rivers Pharmaceuticals and its treatments for hepatitis C. Waksal expects the Three Rivers science to be the backbone of the enterprise. The Wall Street Journal estimated that the deal was worth $100 million. Reuters